NCT05100069 Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
| NCT ID | NCT05100069 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Non-small Cell Lung Cancer (NSCLC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2021-11-01 |
| Primary Completion | 2030-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2021-11-01 with a primary completion date of 2030-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.
Eligibility Criteria
Inclusion criteria Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer. Exclusion criteria Participants who has a history of hypersensitivity to any component of birigatinib.
Contact & Investigator
Study Director
STUDY DIRECTOR
Takeda
Frequently Asked Questions
Who can join the NCT05100069 clinical trial?
This trial is open to participants of all sexes, studying Non-small Cell Lung Cancer (NSCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05100069 currently recruiting?
Yes, NCT05100069 is actively recruiting participants. Contact the research team at medinfoUS@takeda.com for enrollment information.
Where is the NCT05100069 trial being conducted?
This trial is being conducted at Tokyo, Japan.
Who is sponsoring the NCT05100069 clinical trial?
NCT05100069 is sponsored by Takeda. The principal investigator is Study Director at Takeda. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.